By a News Reporter-Staff News Editor at Diabetes Week -- Investigators discuss new findings in Diabetes. According to news reporting from Taoyuan, Taiwan, by NewsRx journalists, research stated, "Current insulin therapy via subcutaneous administration can lead to occasional hypoglycemia and peripheral hyperinsulinemia, due to its nonphysiological route. This study evaluates the feasibility of using bovine insulin and exendin-4 in a form of combination therapy, as orally delivered by nanoparticles composed of chitosan and poly(gamma-glutamic acid) (CS/gamma PGA NPs), to control blood glucose levels in rats with type 2 diabetes mellitus (T2DM) undergoing the oral glucose tolerance test."
The news correspondents obtained a quote from the research from Chang Gung Memorial Hospital, "Experimental results indicate that CS/gamma PGA NPs could enhance the intestinal paracellular permeation; consequently, the exogenous bovine insulin and exendin-4 could be delivered into the liver and pancreas, where they could elicit their glucoregulatory activities. In response to the stimulus of exogenously delivered bovine insulin and the endogenously secreted rat insulin stimulated by the ingested exendin-4, significant glucose utilizations were found in the cardiac and skeletal muscles, resulting in the glucose-lowering effect. Owing to its synergic stimulation effects, the hypoglycemic effect of oral ingestion of NPs containing bovine insulin and exendin-4 was significantly greater than that of the group solely treated with insulin NPs."
According to the news reporters, the research concluded: "Above results demonstrate that oral combination therapy with bovine insulin and exendin-4 improves the modulation of blood glucose levels in T2DM rats, making it highly promising for treating those T2DM patients not adequately controlled by the current insulin therapy."
For more information on this research see: Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials, 2013;34(32):7994-8001. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting E.Y. Chuang, Chang Gung Memorial Hospital, Tao Yuan, Taiwan. Additional authors for this research include G.T.H. Nguyen, F.Y. Su, K.J. Lin, C.T. Chen, F.L. Mi, T.C. Yen, J.H. Juang and H.W. Sung (see also Diabetes).
Keywords for this news article include: Asia, Taiwan, Taoyuan, Diabetes, Proinsulin, Nanoparticle, Endocrinology, Nanotechnology, Peptide Hormones, Combination Therapy, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC